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Objective: Although Markov cohort models represent one of the most common forms of decision-
analytic models used in health care decision-making, correct implementation of such models 
requires reliable estimation of transition probabilities. This study sought to identify consensus 
statements or guidelines that detail how such transition probability matrices should be estimated.
Methods: A literature review was performed to identify relevant publications in the following 
databases: Medline, Embase, the Cochrane Library, and PubMed. Electronic searches were 
supplemented by manual-searches of health technology assessment (HTA) websites in Austra-
lia, Belgium, Canada, France, Germany, Ireland, Norway, Portugal, Sweden, and the UK. One 
reviewer assessed studies for eligibility.
Results: Of the 1,931 citations identified in the electronic searches, no studies met the inclu-
sion criteria for full-text review, and no guidelines on transition probabilities in Markov models 
were identified. Manual-searching of the websites of HTA agencies identified ten guidelines on 
economic evaluations (Australia, Belgium, Canada, France, Germany, Ireland, Norway, Portu-
gal, Sweden, and UK). All identified guidelines provided general guidance on how to develop 
economic models, but none provided guidance on the calculation of transition probabilities. 
One relevant publication was identified following review of the reference lists of HTA agency 
guidelines: the International Society for Pharmacoeconomics and Outcomes Research taskforce 
guidance. This provided limited guidance on the use of rates and probabilities.
Conclusions: There is limited formal guidance available on the estimation of transition proba-
bilities for use in decision-analytic models. Given the increasing importance of cost-effectiveness 
analysis in the decision-making processes of HTA bodies and other medical decision-makers, 
there is a need for additional guidance to inform a more consistent approach to decision-analytic 
modeling. Further research should be done to develop more detailed guidelines on the estima-
tion of transition probabilities.
Keywords: cost-effectiveness, decision models, probability, transitions
Introduction
Health technology assessment (HTA) and medical decision-making, more generally, 
rely on the use of decision-analytic models. Such models synthesize clinical, epide-
miological, quality of life, resource use, and cost data in order to generate estimates 
of health effects and associated costs. Markov models are a popular form of decision-
analytic models which characterize patient cohorts based on a finite number of mutu-
ally exclusive and exhaustive “health states”. Under the Markov property, membership 
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of future health states depends only on the current health 
state, and not on the events that occurred before.1 Movement 
between health states is defined by “transition probabilities”, 
which determine the likelihood of a patient moving from one 
health state to another over a discrete period of time (the 
“cycle length”).1
An illustrative example of a three-state Markov model 
with health states 1, 2, and 3 is presented in Figure 1; an 
example of health states for a model of a general condition 
may be asymptomatic disease, symptomatic disease, and 
death. Movements between health states are governed by a 
matrix P of transition probabilities p
rs
, which describes the 
risk of moving from state r to state s ≠ r at time r over a 
model cycle of length u, and p
rr
, which describes the prob-
ability of remaining in state r at time r over a model cycle 
of length u. One health state (in this case health state 3, and 
usually the health state corresponding to death) will act as 
the “absorbing state”, for which the probability of moving 
to any other state is 0 and the probability of remaining in 
the state is 1.
Measures for cost and outcome can be associated with 
states and transitions to account for resource use during dif-
ferent stages of disease and the associated changes in health 
outcomes. These estimates of costs and outcomes may be 
accumulated over the course of the model and the cost-
effectiveness of health technologies estimated.
The correct implementation of Markov models requires 
reliable and robust estimation of transition probability matri-
ces (TPMs). In the simplest case, transition probabilities can 
be estimated in a straightforward manner using nonpara-
metric methods based on observed counts for movements 
between health states in a data source. Briggs et al2 describe 
the methods for calculating probabilities in this scenario.
However, calculating TPMs is challenging when the 
inputs to the economic evaluation cannot be derived directly 
and completely from a single dataset; for example:
•	 How should TPMs be constructed when not all transitions 
are observed within a dataset?
Briggs et al2 note that feasible transitions might not always 
be observed in all datasets, implying 0% probability of these 
transitions occurring. The authors advise not to exclude 
potential transitions because they were not observed in the 
data. Alternatively, a prior distribution may be specified; 
commonly, 1 is added to each cell count.
•	 How should subgroup analyses be performed in Markov 
cohort models?
Subgroup analysis in Markov cohort models for economic 
evaluation is usually performed based on stratification of data, 
and estimation of transition probabilities at different values of 
t typically requires multiple partitions of the available data. 
This is often not an efficient use of data, and introduces many 
model parameters. An alternative approach is to allow covari-
ate adjustment of the TPM. A growing body of literature has 
described these multi-state parametric models, which can be 
implemented in standard statistical software such as R, but 
have not yet been applied widely within economic evaluations 
for HTA submissions.3–5
•	 How should treatment effects from clinical studies and 
meta-analyses be applied?
It is common to apply relative effects to TPMs to estimate 
the probability of events for an intervention. Such treatment 
effects may be drawn from clinical trials directly or from 
formal evidence synthesis. Relative risks and odds ratios 
(unlike hazard ratios) are specific to the time period for which 
the event probabilities are defined. If the length of the trial 
or study reporting the relative risk (or odds ratio) is not the 
same as cycle length u, then applying this relative risk (or 
odds ratio) directly will be incorrect.6 Price et al6 present an 
adjustment to account for differences between the measured 
time point and the relative risk.
•	 How can we convert between alternative cycle lengths?
It is well known that in order to convert a probability from 
one cycle length to another (e.g., from annual to 6-months), it 
must be done by first converting to a rate.7,8 This is commonly 
achieved using the standard actuarial formula.9 However, 
conversion of a TPM from one cycle length to another is 
nontrivial; applying the actuarial formula to convert TPMs Figure 1 Illustrative example of a three-state Markov model.
1
2
P =
p11 p12 p13
p21 p22 p23
0 0 1
3
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in models with more than two states introduces bias, because 
this ignores competing risk among states.10 More appropriate 
conversion requires taking the root of the matrix,10 or alterna-
tively, choosing a short cycle length such that the probability 
of multiple clinical events occurring during a cycle is very 
small, thereby minimizing the bias.11
•	 How should model calibration be performed if direct 
estimation of inputs is not possible?
The objective of calibration is to “reverse engineer” the 
model of interest; essentially, to find input parameters so 
that the model predicts a known outcome (or outcomes). 
The analyst must make several decisions: there are multiple 
ways to define the objective function for the calibrated 
model, including approaches based on acceptable windows, 
minimizing deviation (absolute or in percentage terms), or 
the specification of likelihood functions. The selection of 
input parameters may also be performed using a number of 
methods. If multiple outcomes are to be calibrated against, 
and their input parameters are not independent, this can 
then become a complex optimization problem.12 Welton and 
Ades13 provide an illustrated example of how to calibrate 
transition probabilities to be consistent with information 
from a particular study.
•	 How should missing data be handled?
A commonly recommended strategy for addressing missing 
data within economic evaluations is multiple imputation.14 
Under multiple imputation, each missing value is replaced 
with multiple predicted values; a vector of M≥2 possible 
values is created.15 M complete datasets are created, each 
with different imputations for the missing data. The data-
sets can then be analyzed together using standard statistical 
methods and uncertainty appropriately characterized using 
Rubin’s rules.15 In order to estimate transition probabilities 
nonparametrically following imputation, the analyst may, 
for example, assume that the observed value is represented 
by the mean of the values across the M datasets. However, 
this approach fails to recognize the uncertainty associated 
with the imputation process itself and as a consequence 
will underestimate uncertainty in the analysis. An obvious 
approach may be to estimate separate TPMs for each of the M 
datasets, and then sample between these alternative datasets 
in probabilistic sensitivity analysis. However, we are not 
aware of any studies assessing this.
Transparent and consistent decision-making relies on 
the availability of an accepted methodological approach to 
the calculation of TPMs; while individual researchers have 
contributed substantially to the discussion on these topics, 
the authors of the present study are not aware of any formal 
consensus statements or guidelines addressing questions 
such as those mentioned earlier. This targeted literature 
review therefore, sought to identify consensus statements or 
guidelines detailing how TPMs should be estimated for use 
in Markov models in the context of the economic evaluation 
of medical interventions.
Methods
A targeted literature review was performed to answer the 
following research question:
•	 What consensus statements or guidelines are available to 
inform the calculation of transition probabilities for use in 
Markov models for the economic evaluation of medical 
interventions?
Consensus statements were defined as “documents 
containing suggestions or recommendations based on the 
collective opinion of an expert panel” and guidelines as 
“systematically developed statements to assist researchers, 
HTA bodies, and other professionals in decisions about 
appropriate methodological approaches”.
Search methods
A base strategy was developed and refined to specifically 
target publications relevant to the research question.
Electronic database search
Search strategies specific to each database were designed to 
focus on retrieval of the published articles most likely to be 
relevant to the research question. The search strategies were 
designed and run by an experienced medical librarian.
The following electronic databases were searched:
•	 Medline (OvidSP)
•	 Medline In-Process Citations & Daily Update (OvidSP)
•	 Embase (OvidSP)
•	 PubMed
•	 The Cochrane Library, which includes six databases 
(Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, Cochrane Meth-
odology Register, Database of Abstracts of Reviews of 
Effects, Health Technology Assessment Database, NHS 
Economic Evaluation Database)
Electronic searches were limited to English language publica-
tions. No country or time limits were applied. Details on the 
search strategy can be found in Figure S1.
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HTA website search
The electronic search was supplemented by a literature search 
for relevant guidelines on HTA agency websites. The HTA 
agencies whose websites were searched are listed in Table 1. 
Reference lists of identified HTA guidelines were screened to 
identify additional relevant publications. No language limit 
was applied to searches of HTA websites.
Study selection
Identified publications were screened by one reviewer, with any 
publication considered to be informative to the research ques-
tion being included. Study selection occurred in three phases:
•	 Potentially relevant publications were identified based 
on their title; any title clearly irrelevant was discarded at 
this stage.
•	 Abstracts or keywords were used to screen the remain-
ing articles in order to identify relevant publications for 
full-text review.
•	 The full text of each potentially relevant publication was 
reviewed.
Studies were included if they were guidelines or consen-
sus statements on the calculation of transition probabilities 
from either clinical endpoints of clinical trials or from clini-
cal parameters of indirect/multiple treatment comparisons 
in Markov models. Publications that were not produced on 
behalf of professional organizations, expert panels, or HTA 
bodies were excluded.
Results
Electronic database search
The electronic database search identified 3,636 publica-
tions; 1,931 unique publications were identified following 
deduplication (Table 2).
Of the 1,931 unique publications identified, 1,788 pub-
lications were excluded on the basis of title review and 143 
publications were excluded on the basis of abstract review. No 
guidelines on the estimation of transition probabilities for use 
in Markov models were identified via the electronic database 
search (Figure 2). However, 56 studies were considered to 
be of broad relevance, typically reflecting the viewpoints 
of individual authors or independent research groups as 
opposed to formal guidelines or recommendations. A list of 
the 56 publications considered to be of broad relevance can 
be found in Table S1.
HTA website search
The HTA website search identified 10 guidelines on eco-
nomic evaluation. However, no identified guidelines included 
Table 1 HTA agency websites considered
Country HTA agency
Australia Pharmaceutical Benefits Advisory Committee (PBAC)
Belgium Belgian Health Care Knowledge Centre (KCE)
Canada Canadian Agency for Drugs and Technologies in Health (CADTH)
France The French National Authority for Health (HAS)
Germany Institute for Quality and Efficiency in Health Care (IQWiG) 
Ireland National Centre for Pharmacoeconomics (NCPE)
Norway The Norwegian Medicines Agency (NoMA)
Portugal National Authority of Medicines and Health Products (INFARMED)
Sweden Dental and Pharmaceutical Benefits Agency (TLV)
UK* National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC), All Wales Medicines Strategy 
Group (AWMSG)
Note: *Including NICE Decision Support Unit reports.
Abbreviation: HTA, health technology assessment.
Table 2 Results of the electronic database search
Electronic database Records identified After deduplication
Medline 1,057 1,043
Embase 1,422 775
PubMed 1,098 111
The Cochrane Library 59 2
Total 3,636 1,931
Figure 2 Flow diagram of the screening process for the electronic database search.
3,636
citations
identified
1,931 titles
screened
after
removal of
duplicates
143
abstracts
screened
No relevant
full-text
articles
identified
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 guidance or recommendations on the calculation of TPMs. 
One relevant publication was identified following review of 
the reference lists of guidelines selected through the HTA 
website search.8 The International Society for Pharmaco-
economics and Outcomes Research - Society for Medical 
Decision Making (ISPOR-SMDM) Modeling Good Research 
Practices Task Force recommend that the conversion of transi-
tion probabilities from one cycle length to another should be 
done through rates. However, no further details are provided.
Discussion
The aim of the targeted review was to identify formal recom-
mendations, such as consensus statements or guidelines, to 
inform the calculation of transition probabilities for use in 
Markov models for the economic evaluation of medical inter-
ventions. One relevant publication was identified, in which the 
ISPOR-SMDM Modeling Good Research Practices Task Force 
recommended that the conversion of transition probabilities 
from one cycle length to another should be done through rates. 
However, many key questions around the estimation of TPMs 
for health care decision-making remain unanswered.
We searched a wide variety of data sources including 
electronic databases and HTA agency websites to identify 
relevant studies. However, our approach cannot be considered 
systematic. Our targeted review might not have captured all 
studies of interest given that relevant literature in this field is 
not always formally published as journal articles. Also, our 
searches of HTA agency websites were limited to ten; so it 
might be that relevant consensus statements or guidelines are 
available on unsearched HTA agency websites. Finally, our 
electronic database searches were limited to English language 
only, thus potentially leading to language bias and exclusion 
of relevant articles published in other languages.
This review was limited to modeling methods for medical 
interventions, and only included formal recommendations 
such as consensus statements or guidelines; we are aware 
that a substantial body of literature exists on the topic of 
estimating TPMs in the financial, engineering, and statistical 
fields, and from independent authors in the health eco nomics 
community which would not have been identified by our 
search protocol.
Therefore, it is recommended that additional research be 
conducted to consolidate and build on existing knowledge 
on this topic. An expert panel or working group should be 
convened to identify key circumstances in which the estima-
tion of transition probabilities is not straightforward, or where 
the most appropriate approach is considered contentious. A 
broad systematic review of methodological publications on 
the topic of TPMs spanning all academic fields should be 
undertaken, and formal recommendations developed on the 
basis of the review, and as part of an iterative process amongst 
the expert panel or working group.
In the absence of consensus statements or guidelines, 
currently developed Markov models may utilize approaches 
that reduce accuracy, introduce additional uncertainty, or 
underestimate the uncertainty that exists. The develop-
ment of formal guidance on the estimation of TPMs for 
health care decision-making would allow a more consistent 
approach to decision-analytic modeling, and therefore to 
decision-making.
Acknowledgments
We would like to thank Richard Grieve for the critical 
review of this manuscript and Dave Fox for developing the 
search strategy. This study was sponsored by Takeda Phar-
maceuticals International AG. The abstract of this article 
was presented as a poster at the International Society for 
Pharmacoeconomics and Outcomes Research 19th Annual 
European Congress in 2016. The poster’s abstract has also 
been published.16
Disclosure
HCS is a permanent employee of Takeda Pharmaceuticals 
International AG. EO, KKC, EH, and DT have received con-
sulting fees from Takeda Pharmaceuticals International AG. 
The authors report no other conflicts of interest in this work.
References
 1. Briggs A, Sculpher M. An introduction to Markov Modelling for eco-
nomic evaluation. Pharmacoeconomics. 1998;13(4):397–409.
 2. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for 
decision trees with multiple branches: use of the Dirichlet distribution 
in a Bayesian framework. Med Decis Making. 2003;23(4):341–350.
 3. Jackson CH. Multi-state models for panel data: the MSM package for 
R. J Stat Softw. 2011;38(8):1–29.
 4. Meira-Machado L, Cadarso-Suárez C, de Uña-Alvarez J. Tdc.msm: an 
R library for the analysis of multi-state survival data. Comput Methods 
Programs Biomed. 2007;86(2):131–140.
 5. Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, Andersen PK. 
Multi-state models for the analysis of time-to-event data. Stat Methods 
Med Res. 2009;18(2):195–222.
 6. Price MJ, Welton NJ, Ades AE. Calculating Markov transition prob-
abilities when treatment effects are reported as relative risks with a 
different cycle time. Available from: http://www.bristol.ac.uk/social-
community-medicine/media/mpes/price-calculating-08.pdf. Accessed 
July 19, 2016.
 7. Miller DK, Homan SM. Determining transition probabilities: confusion 
and suggestions. Med Decis Making. 1994;14(1):52–58.
 8. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: 
a report of the ISPOR-SMDM modeling good research practices task 
force-3. Value Health. 2012;15(6):812–820.
 9. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic 
modelling. Pharmacoeconomics. 2007;25(1):3–6.
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
52
 o
n 
25
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
542
Olariu et al
10. Chhatwal J, Jayasuriya S, Elbasha EH. Changing cycle lengths in 
state-transition models: challenges and solutions. Med Decis Making. 
2016;36(8):952–964.
11. O’Mahony JF, Newall AT, van Rosmalen J. Dealing with time in health 
economic evaluation: methodological issues and recommendations for 
practice. Pharmacoeconomics. 2015;33(12):1255–1268.
12. Taylor DC, Pawar V, Kruzikas D, et al. Methods of model calibration: 
observations from a mathematical model of cervical cancer. Pharma-
coeconomics. 2010; 28 (11):995–1000.
13. Welton NJ, Ades AE. Estimation of Markov chain transition probabilities 
and rates from fully and partially observed data: uncertainty propaga-
tion, evidence synthesis, and model calibration. Med Decis Making. 
2005;25(6):633–645.
14. Gomes M, Díaz-Ordaz K, Grieve R, Kenward MG. Multiple imputation 
methods for handling missing data in cost-effectiveness analyses that 
use data from hierarchical studies an application to cluster randomized 
trials. Med Decis Making. 2013;33(8):1051–1063.
15. Rubin DB. An Overview of Multiple Imputation. In: Proceedings 
of the Survey Research Methods Section of the American Statistical 
Association. 1988:79–84. Available from: https://www.amstat.org/Sec-
tions/Srms/Proceedings/papers/1988_016.pdf. Accessed September 1, 
2016.
16. Olariu E, Cadwell KK, Fox D, et al. Recommendations for the calcu-
lation of transition probabilities in Markov cohort models: a targeted 
literature review. Value in Health. 2016;19(7):A373.
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
52
 o
n 
25
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
543
Transition probabilities in Markov cohort models
Supplementary materials
Medline
Searched 25/05/16 via OvidSP interface.
Limited to English language.
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid 
MEDLINE(R)<1946 to Present>
Search strategy:
1 (transition adj2 (probabilit$ or intensit$)).ti,ab. (2,490)
2 markov$.ti,ab. (17,383)
3 (((multi adj1 state) or (state adj1 transition) or cohort or decision or (decision adj1 analytic)) adj1 model$).ti,ab. (3,477)
4 (matrix or matrices).ti,ab. (3,15,632)
5 or/2–4 (3,34,908)
6 1 and 5 (1,091)
7 limit 6 to english language (1,057)
1,057 results.
Embase
Searched 25/05/16 via OvidSP interface.
Limited to English language.
Database: Embase <1996 to 2016 Week 21>
Search strategy:
1 (transition adj2 (probabilit$ or intensit$)).ti,ab. (2,832)
2 markov$.ti,ab. (20,059)
3 (((multi adj1 state) or (state adj1 transition) or cohort or decision or (decision adj1 analytic)) adj1 model$).ti,ab. (4,710)
4 (matrix or matrices).ti,ab. (3,60,188)
5 or/2–4 (3,82,938)
6 1 and 5 (1,731)
7 limit 6 to english language (1,682)
8 limit 7 to embase (1,422)
1,422 results.
PubMed
Searched 25/05/16 online at https://www.ncbi.nlm.nih.gov/pubmed/advanced
Limited to English language.
Search strategy:
#8 (#6 and #7) (1,098)
#7 “english”[Language] (2,15,23,839)
#6 (#1 and #5) (1,129)
#5 (#2 or #3 or #4) (4,26,135)
#4 (matrix[Title/Abstract] OR matrices[Title/Abstract]) (3,14,406)
#3  (((((multi-state[Title/Abstract] OR “multi state”[Title/Abstract] OR state-transition[Title/Abstract] OR “state 
transition”[Title/Abstract] OR cohort[Title/Abstract] OR decision[Title/Abstract] OR decision-analytic[Title/Abstract]) 
AND model*[Title/Abstract])))) (99,167)
#2 markov*[Title/Abstract] (17,498)
#1  ((((“transition probability”[Title/Abstract] OR “transition probabilities”[Title/Abstract] OR “transition intensity”[Title/
Abstract] OR “transition intensities”[Title/Abstract) (2,260) 
1,098 results.
Figure S1 (Continued)
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Table S1 Potentially relevant publications identified via the electronic searches
Reference Title
Aalen et al1 Covariate adjustment of event histories estimated from Markov chains: the additive approach
Alam et al2 Investigating the impact of structural changes in a nice single technology appraisal cost-effectiveness model
Alarid-Escudero et al3 Calibration of piecewise Markov models using a change-point analysis through an iterative convex 
optimization algorithm
Albert and Waclawiw4 A two-state Markov chain for heterogeneous transitional data: a quasi-likelihood approach
Allignol et al5 A competing risks approach for nonparametric estimation of transition probabilities in a non-Markov 
illness-death model
Andersen and Pohar Perme6 Inference for outcome probabilities in multi-state models
Black et al7 Determining transition probabilities from mortality rates and autopsy findings
Borgan8 Estimation of covariate-dependent Markov transition probabilities from nested case-control data. (Erratum 
is reference 9)
Borgan9 Erratum: Estimation of covariate-dependent Markov transition probabilities from nested case-control data 
(Original paper is reference 8)
Boruvka and Cook10 Sieve estimation in a Markov illness-death process under dual censoring
Cohen11 On estimating the equilibrium and transition probabilities of a finite-state Markov chain from the same data
Cooper et al12 Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach
Craig and Sendi13 Estimation of the transition matrix of a discrete-time Markov chain
Dabrowska and Ho14 Confidence bands for comparison of transition probabilities in a Markov chain model
Debosscher15 Unifying stochastic Markov process and its transition probability density function
Denton and Spencer16 Modeling the age dynamics of chronic health conditions: life-table-consistent transition probabilities and 
their application
Diaby et al17 Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the 
absence of individual patient data: a tutorial
Gaveau and Schulman18 Multiple phases in stochastic dynamics: geometry and probabilities
Gupta et al19 Transition probability estimation using repeated sampling from a fitted mixed model
Gupta et al20 Generalized implementation of Em algorithm for estimation of transition probability matrix
Hawkins and Han21 Estimating transition probabilities from aggregate samples plus partial transition data
Healy and Engler22 Modeling disease-state transition heterogeneity through Bayesian variable selection
Huang23 Integrated analysis of incidence, progression, regression and disappearance probabilities
Iacobelli and Carstensen24 Multiple time scales in multi-state models
Kassteele et al25 Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic 
disease modeling
Kaushik et al26 A methodology to monitor the changing trends in health status of an elderly person by developing a 
Markov model
Li and Pack27 An application of Markov models in estimating transition probabilities for postmenopausal women with 
osteoporosis
(Continued)
Cochrane Library
Includes Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), 
Cochrane Central Register of Controlled Trials (CENTRAL), Health Technology Assessment Database (HTAD), NHS 
Economic Evaluations Database (NHSEED).
Searched 25/05/16 online at http://onlinelibrary.wiley.com/cochranelibrary/search/advanced
Search strategy:
#1 (transition near/2 (probabilit* or intensit*)):ti,ab (76)
#2 markov*:ti,ab (672)
#3  (((multi near/1 state) or (state near/1 transition) or cohort or decision or (decision near/1 analytic)) near/1 model*):ti,ab 
(358)
#4 (matrix or matrices):ti,ab (3,581)
#5 #2 or #3 or #4 (4,537)
#6 #1 and #5 (59)
59 total results all from CENTRAL. No results for CDSR, DARE, HTAD, or NHSEED.
Figure S1 Search strategy.
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Reference Title
Limwattananon and Limwattananon28 Constructing a state-transition model for an economic evaluation of cancer treatments
McCombs29 Pharmacoeconomics: what is it and where is it going?
Meidani and Ghanem30 Uncertainty quantification for Markov chain models
Meira-Machado et al31 Nonparametric estimation of transition probabilities in a non-Markov illness-death model
Meira-Machado et al32 Multi-state models for the analysis of time-to-event data
Miller and Homan33 Determining transition probabilities: confusion and suggestions
Milne34 Pharmacoeconomic models in disease management. A guide for the novice or the perplexed
Moussa et al35 Measuring the change in contingency tables using Markov models application to the effect of preceding 
conception on the next one
Muenz and Rubinstein36 Markov models for covariate dependence of binary sequences
Nagylaki37 The distribution of sojourn times in finite absorbing Markov chains
Neine et al38 Bayesian calibration method to estimate transition probabilities for a Markov model based on a continuous 
outcome measure: application in Parkinson’s disease
Ng and Cook39 Modeling two-state disease processes with random effects
O’Mahony et al40 Dealing with time in health economic evaluation: methodological issues and recommendations for practice
Oppe et al41 Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-
effectiveness model
Paes and Lima42 A SAS macro for estimating transition probabilities in semiparametric models for recurrent events
Putter et al43 Tutorial in biostatistics: competing risk and multi-state models
Regnier and Shechter44 State-space size considerations for disease-progression models
Rodriguez-Girondo and Una-Alvarez45 A nonparametric test for Markovianity in the illness-death model
Rodriguez-Girondo and Una-Alvarez46 Testing Markovianity in the three-state progressive model via future-past association
Rodriguez-Girondo and Una-Alvarez47 Methods for testing the Markov condition in the illness-death model: a comparative study
Rosychuk et al48 Comparison of variance estimation approaches in a two-state Markov model for longitudinal data with 
misclassification
Rosychuk and Thompson49 Bias correction of two-state latent Markov process parameter estimates under misclassification
Saint-Pierre et al50 The analysis of asthma control under a Markov assumption with use of covariates
Spitoni et al51 Estimation and asymptotic theory for transition probabilities in Markov renewal multi-state models
Tattar and Vaman52 Testing transition probability matrix of a multi-state model with censored data
Tattar and Vaman53 The k-sample problem in a multi-state model and testing transition probability matrices
Titman54 Transition probability estimates for non-Markov multi-state models
Tsang et al55 Estimating Markov chain transition matrices in limited data samples: a Monte Carlo experiment
Welton and Ades56 Estimation of Markov chain transition probabilities and rates from fully and partially observed data: 
uncertainty propagation, evidence synthesis, and model calibration
Table S1 (Continued)
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